ESG Report 2025

26 Utility Model Patents 12 Invention Patents 95 Design Patents 20 The United Laboratories has continued to achieve breakthroughs in pharmaceutical R&D and innovation in production processes, making intellectual property protection a key element in safeguarding innovation outcomes and maintaining core competitiveness. To strengthen intellectual property management and fully realise the value of intangible assets such as patents and trademarks, the Group formulated “The United Laboratories Intellectual Property Management Policy” in accordance with laws and regulations including the “Patent Law of the People's Republic of China”, Trademark Law of the People's Republic of China”, “Copyright Law of the People's Republic of China” and “Anti-Unfair Competition Law of the People's Republic of China”. The policy standardises the application, maintenance, utilisation and protection of intellectual property and provides solid support for the Group's continued innovation-driven development. The Group has established an Intellectual Property Department to take charge of the centralised management of intellectual property matters, including the application for and maintenance of patents and intellectual property signs, and to supervise relevant units in stopping, reporting and collecting evidence of infringement and cooperating with national crackdowns on infringement. In addition, the Group has established an Information and Patent Team focusing on the protection of patented technologies such as techniques, processes and formulations to ensure that innovative achievements are adequately protected. For trademark management, the Group's Legal Centre is responsible for trademark registration, renewal, authorisation, rights protection and related matters. All uses of trademarks must be reviewed by the Legal Centre to ensure standardised use and effective control. When printing materials bearing trademarks, such as product packaging, the Group works only with reputable printers and strictly destroys defective and obsolete trademark materials to prevent external circulation and misuse by unlawful manufacturers, thereby protecting the Group's lawful trademark rights and brand image. As at the end of the Reporting Period, the Group had successfully obtained a total of 127 patents, as detailed below. 5.5 Intellectual Property Management The Group regards the cultivation of intellectual property awareness as an important component of building an innovation culture. Through regular training on intellectual property, case sharing and policy interpretation, it enhances employees' understanding of the importance of intellectual property protection, helps R&D personnel master the fundamentals of patent mining, portfolio planning and application, and fosters a culture of respect for innovation and protection of intellectual property rights. At the same time, the Group actively monitors the latest policy developments and industry trends in the field of intellectual property and adjusts its internal management strategies in a timely manner to ensure that intellectual property management remains aligned with legal requirements and industry development. The Group has established a Clinical Research Centre and a quality management system covering the full process of clinical trials. The Centre is mainly responsible for formulating clinical development strategies and pathways for all clinical trial projects of the Group, as well as research protocol design, organisation and implementation of clinical trials, project management, monitoring and quality management. All of the Group's clinical trials strictly follow relevant regulations and ethical requirements including the “Declaration of Helsinki of the World Medical Association”, the “Civil Code of the People's Republic of China”, the “Drug Administration Law of the People's Republic of China”, the “Measures for the Administration of Drug Registration”, “Quality Control of Clinical Trials of Drugs Measures for Ethical Review of Life”, and “Measures for Ethical Review of Life Sciences and Medical Research Involving Human Subjects”, placing the rights, interests and safety of trial subjects as the highest priority. We also require that all drug clinical trials obtain the relevant trial approval and formulate scientific, ethical, compliant and operable clinical trial protocols and work plans, including but not limited to project management plans, monitoring plans, data management plans and risk management plans. These plans clearly set out procedures relating to source data review, verification and traceability, monitoring frequency and requirements, collaborative monitoring and auditing. In addition, all trials must be reviewed by drug clinical trial institutions and ethics committees to ensure that all trial subjects sign informed consent forms. The Group attaches great importance to the protection of trial subjects' personal information and strictly implements confidentiality measures such as anonymisation and coding to ensure the security of research project data and minimise the potential risks arising from privacy leakage. For details, please refer to “5.4 Information Security and Data Protection” of this Report. As at the end of the Year, the Group was conducting 13 clinical trials for new drugs, while several additional clinical trials were about to commence. Throughout the process, we will continue to implement mechanisms for quality monitoring, auditing, feedback and improvement, thereby ensuring the integrity and compliance of clinical trials. 5.6 Medical Ethics The United Laboratories International Holdings Limited 2025 Environmental, Social and Governance Report